News | October 31, 2022
Sustaining growth momentum is key for Navin Fluorine: ICICI Securities
NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.
NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.
The company's long-term strategy is on science, technology and innovation and the company's strategy relating to this is on track
On the Capex front, the company has invested Rs. 416 crore in the first half and it is broadly in line with our guidance for the two years around Rs. 2,000 crore across all the subsidiaries and divisions
The ANDA was filed as 'First to File' submission on NCE-1 date.
We are launching the five new products in the new manufacturing facility and they're all pharmaceuticals and this should lead to an increase in pharma numbers.
This rapid analytical technique provides additional information about the polymorph and solid-state properties of active pharmaceutical ingredients (APIs)
Margins under pressure - Price erosion, shelf stock adjustments and inventory pare down in US biz impacted margins.
Both the plants have a total Capex of Rs. 75 crore and expected production timeline is Q3 FY23
Lupin is the 6th largest company in the Indian Pharmaceutical Market
A newly revealed mechanism by Weizmann Institute of Science of ketamine’s action on potassium channels in neurons may lead to improved therapies for depression
Subscribe To Our Newsletter & Stay Updated
